Evaluation of the validity of Ag PANBIO-COVID19 in the diagnosis of SARS-CoV-2 infection in asymptomatic or mildly infected patients


Por: Gras-Valenti, P, Vidal, I, Montiel-Higuero, I, Escribano, I, Algado-Selles, N, Chico-Sanchez, P, Ventero, M, Jimenez-Sepulveda, N, Molina-Pardines, C, Merino-Lucas, E, Sanchez-Paya, J and Rodriguez, J

Publicada: 1 dic 2021 Ahead of Print: 22 sep 2021
Resumen:
Objective. To assess the validity of SARS-CoV-2 Antigen (Ag) detection for the diagnosis of SARS-CoV-2 infection in mildly infected or asymptomatic patients. Material and methods. Observational study to evaluate diagnostic tests. Non-hospitalized patients with indication for diagnostic testing for SARS-CoV-2 infection were included. The diagnostic test to be evaluated was the determination of Ag and as a reference standard to determine the presence of viral RNA the RT-PCR was used. Results. A total of 494 patients were included. Of these 71.5% (353/494) had symptoms and 28.5% (141/494) were asymptomatic (presurgery screening (35/494) and confirmed case-contact (106/494). The overall sensitivity of the Ag test was 61.1% and the specificity was 99.7%. The sensitivity and specificity in the asymptomatic group were 40% and 100% respectively, and in the symptomatic group 63.5% and 99.6% respectively. In turn, the sensitivity and specificity in the group of symptomatic patients varied according to the time of symptom evolution: in patients with recent symptoms, they were 71.4% and 99.6% respectively, while in patients with symptoms of more than 5 days of evolution, they were 26.7% and 100% respectively. In all groups studied, the presence of antigen is associated with a high viral load (Ct<30 cycles). Conclusions. The use of Ag detection test is not indicated for the diagnosis of SARS-CoV-2 infection in asymptomatic patients or with symptoms of more than 5 days of evolution, but it could be useful in patients with symptoms of 1-5 days of evolution.

Filiaciones:
:
 Hosp Gen Univ Alicante, Inst Invest Sanitaria & Biomed Alicante ISABIAL, Serv Med Prevent, Unidad Epidemiol, Alicante, Spain

:
 Hosp Gen Univ Alicante, Inst Invest Sanitaria & Biomed Alicante ISABIAL, Serv Microbiol, Alicante, Spain

:
 Hosp Gen Univ Alicante, Inst Invest Sanitaria & Biomed Alicante ISABIAL, Unidad Admis & Documentac Clin, Alicante, Spain

Escribano, I:
 Hosp Gen Univ Alicante, Inst Invest Sanitaria & Biomed Alicante ISABIAL, Serv Microbiol, Alicante, Spain

:
 Hosp Gen Univ Alicante, Inst Invest Sanitaria & Biomed Alicante ISABIAL, Serv Med Prevent, Unidad Epidemiol, Alicante, Spain

:
 Hosp Gen Univ Alicante, Inst Invest Sanitaria & Biomed Alicante ISABIAL, Serv Med Prevent, Unidad Epidemiol, Alicante, Spain

:
 Hosp Gen Univ Alicante, Inst Invest Sanitaria & Biomed Alicante ISABIAL, Serv Microbiol, Alicante, Spain

:
 Hosp Gen Univ Alicante, Inst Invest Sanitaria & Biomed Alicante ISABIAL, Serv Med Prevent, Unidad Epidemiol, Alicante, Spain

:
 Hosp Gen Univ Alicante, Inst Invest Sanitaria & Biomed Alicante ISABIAL, Serv Microbiol, Alicante, Spain

:
 Hosp Gen Univ Alicante, Inst Invest Sanitaria & Biomed Alicante ISABIAL, Unidad Enfermedades Infecciosas, Alicante, Spain

:
 Hosp Gen Univ Alicante, Inst Invest Sanitaria & Biomed Alicante ISABIAL, Serv Med Prevent, Unidad Epidemiol, Alicante, Spain

:
 Hosp Gen Univ Alicante, Inst Invest Sanitaria & Biomed Alicante ISABIAL, Serv Microbiol, Alicante, Spain
ISSN: 02143429





REVISTA ESPANOLA DE QUIMIOTERAPIA
Editorial
SOCIEDAD ESPANOLA QUIMIOTERAPIA, UNIV COMPLUTENSE MADRID, MICROBIOLOGY DEPT, SCHOOL MEDICINE, AVDA COMPLUTENSE S/N, MADRID, 28040, SPAIN, España
Tipo de documento: Article
Volumen: 34 Número: 6
Páginas: 618-622
WOS Id: 000747675600006
ID de PubMed: 34549577
imagen Bronze, Green Published

MÉTRICAS